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Abstract
In the novel dosage form development, quality is the key criterion in pharma-
ceutical industry. The quality by design tools used for development of the quality 
products with tight specification and rigid process. The specifications of statistical 
tools are essentially based upon critical process parameters (CPPs), critical material 
attributes (CMAs), and critical quality attributes (CQAs) for the development of 
quality products. The application of quality by design in pharmaceutical dosage form 
development is systematic, requiring multivariate experiments employing process 
analytical technology (PAT) and other experiments to recognize critical quality 
attributes depend upon risk assessments (RAs). The quality by design is a modern 
technique to stabilize the quality of pharmaceutical dosage form. The elements of 
quality by design such as process analytical techniques, risk assessment, and design 
of experiment support for assurance of the strategy control for every dosage form 
with a choice of regular monitoring and enhancement for a quality dosage form. This 
chapter represents the concepts and applications of the most common screening 
of designs/experiments, comparative experiments, response surface methodology, 
and regression analysis. The data collected from the dosage form designing during 
laboratory experiments, provide the substructure for pivotal or pilot scale develop-
ment. Statistical tools help not only in understanding and identifying CMAs and 
CPPs in product designing, but also in comprehension of the role and relationship 
between these in attaining a target quality. Although, the implementation of statisti-
cal approaches in the development of dosage form is strongly recommended.
Keywords: Quality by design, Critical quality attributes, Critical process attributes, 
Critical material attributes, Design of experiments, Smart drug delivery
1. Introduction
In an endeavour to fight various pathological manifestations, medicaments have 
been administered via various possible routes [1]. Experimental designs techniques 
have long been used for the optimization of various processes and the development 
of smart drug delivery system such as the factorial designs since 1926 [2], the designs 
for screening since 1946 [3], the central composite designs since 1951 [4], and the 
mixture designs since 1958 [5]. According to Joseph Juran, most of the quality prob-
lems are associated with the way by which a pharmaceutical smart drug delivery was 
designed. A poorly designed pharmaceutical dosage form will show poor efficacy 
and safety, no matter how many analyses or tests have been done to check its quality.
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The quality by design (QbD) is a systemic approach for the development of 
pharmaceutical formulations that starts with predefined objectives and emphasizes 
process and product comprehension and process control, based on quality risk 
management and sound science [6]. The food and drug administration guidance, 
such as pharmaceutical product development (ICH Q8), quality risk evaluation 
(ICH Q9), pharmaceutical quality systems (ICH Q10), the briefly highlighted ICH 
approach to the achieve quality of product through QbD [7], and development and 
manufacture of drug substances (ICH Q11) [8]. The QbD based approach will pro-
vide scientific understanding and knowledge to support smart drug delivery system 
development [9]. The prime goals of QbD for pharmaceuticals may include: (a) to 
attain meaningful product and quality specification; (b) to enhance process ability 
and reduce product variability; (c) to enhance smart dosage form development 
and manufacturing efficiencies, and (d) to increase cause-effect investigation and 
regulatory flexibility [6]. The QbD is used to establish the relationship of product 
performance with the process and product attributes [7, 10]. The applications of 
QbD in pharmaceutical smart drug delivery system development is systematic, 
requiring multivariate experiments employing process analytical technology (PAT) 
and other experiments to recognize critical quality attributes (CQAs) depend upon 
risk assessments (RAs) [7].
The smart dosage form design and process development cannot be distinguished 
since dosage form cannot become a product unaccompanied by a defined process. 
The production process needs to produce a desired standard product typically 
requires multiple units operating conditions and operations [11]. The outline has to 
contain all the factors that require to be contemplated for the design of the process. 
The process factors which cause a vital impact on the quality of the product if 
changes are contemplated as the critical process attribute (CPAs). The process fac-
tor variability, which causes a vital impact on the critical quality of the ingredients 
should be controlled and monitored, at all times to make sure the process for the 
targeted quality [6, 11].
2. Basic elements of quality by design
2.1 Set the standard profile for the target smart dosage form
A target standard profile for smart dosage form describes how a smart dosage 
form will be utilized by the end-user. A systematically developed standard profile 
can ensure the arrangement of objectives across departments of the company, 
advance development of timelines, reduction of risks, and finally lead to an optimal 
smart dosage form. A targeted standard product profile is very important for smart 
drug delivery development due to the variety of administrations and the variety of 
possible end-user (patients, nurses, physicians, and pharmacists) [12].
2.2 Recognition of the critical quality attributes (CQAs)
The next step in QbD for smart dosage form development is recognition of 
the critical quality attributes (CQAs). CQAs are physical, chemical, biological,  
or microbiological characteristics or properties of the pharmaceutical smart 
drug delivery system (in-process or finished) that must be within specified 
standards to ensure quality. CQAs may include identification, content, assay, 
uniformity, solvents, degradation, products, dissolution or drug release, mois-
ture content, moisture uptake, microbial limits, and other properties such as 
color, size, shape, etc. [9, 13].
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2.3 Smart dosage form design and development
The physic-chemical and pharmacological properties of the medicaments 
determine the critical attributes for novel dosage form development. The objec-
tives of the novel dosage form development by using QbD for identification of 
attributes and to achieve desired patient requirements that the resultant product 
should possess to exhibit intended therapeutic response. The smart dosage form 
development must invariably be scientific, systemic, and with basic risk manage-
ment facilitation to achieve these predefined objectives. The CQAs identification is 
strongly and thoroughly based on the understanding of product and manufacturing 
process. These CQAs must be controlled to get reproducible and desired results. 
Table 1 summarizes the different CQAs for medicaments, additives, in-process 
Attribute (CMAs, CQAs & CPAs) Comments
Drug-related
Indication Note if target patients may have limitations (e.g., sodium 
hydrochloride and hypertension)
Types of the route of 
administration
May impact the acceptability of drug product (e.g., the tablet is more 
preferred than parenteral)
Range of dose, frequency of 
dosing, duration of therapy
The concentration, duration of therapy, and frequency of dosing may 
affect the use of some additives (are these outside the statutory use 
levels?)
Pharmacokinetic properties 
(in-vitro/in-vivo)
Is activity associated or toleration with total exposure or the plasma 
concentration? For novel drug delivery formulations, what is the 
required profile?
Drug combination which may 
be designed or mixed for the 
formulation
Are there possible incompatibilities?
Dosage form-related
pH, tonicity, site of application etc.
Administration ante/post cibum 
(oral), need to reconstitute/dilute 
and with what?
Packaging types (single/multi-dose 
packaging)
If more than a single, will be available at the initial stage? Does 
existing machinery work for packaging? Will the packaging be a 
kit (with a device, diluent, etc.)? Are there any considerations for 
disposal (may differ for various regions)? Is functional labelling 
required (e.g., anti-counterfeiting measures, freeze indicators, etc.)?
Storage conditions Include in-use constraints and stability requirements (e.g., 
requirement of secondary packaging to protect from light, “do not 
freeze”)
Requirements for shipping Are there any limitations (susceptibility to shaking, temperature 
excursion, etc.)?
Legitimate-related
Liberty to operate Does the process or product contravene any patents, copyright, and 
applications?
Manufacturing-related
Cost of the product It should cover any royalties as appropriate
The machinery required for 
manufacture
Will the process according to existing machinery?
Processing time for the dosage 
form
Required to consider sterility. Also, may be a matter for some 
processes (e.g., freeze-drying).
Table 1. 
Different critical attributes to formulate a novel dosage form [12].
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Figure 1. 
The fundamental approach of QbD for designing of a pharmaceutical dosage form.
materials, and dosage form [14, 15]. On the basis of suitable statistical methods such 
as DoE (design of experiments), proper risk assessment, and management tools can 
escort to a good and knowledge-based smart dosage form development. Further, 
understanding of CQAs helps to set up flexible and meaningful regulatory product 
specifications. Knowledge of smart drug delivery development can facilitates QbD 
and increase the manufacturing capability (Figure 1) [16].
2.4 Critical process attributes (CPAs)
To develop an optimal manufacturing procedure, all the critical process attributes 
including facilities, equipment, manufacturing variables, and material transfer 
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should be considered. Pulverization, homogenization time/mixing, type of mixer, 
and energy input are the major critical attributes in the manufacturing of novel dos-
age form. The process attributes using these associated factors require be identifying 
and carefully controlling to formulate batches with reproducible quality [17].
Size reduction of the material may be affected by the types of mill used. 
Different types of material need a special type of mill for pulverization such as 
lignocellulosic biomass material (like wood) required ‘fine grinding’ (less than 
100 μm) [18] but in other studies, the ‘fine grinding’ has been used for particle 
sizes up to 1 mm [19–21]. The excess temperature during processing can increase 
the degradation of ingredients [22, 23], while less temperature can cause the failure 
of the process due to drug solubility issues [24]. Mixing speed and time is a critical 
attribute to develop a smart dosage form. For optimizing the mixing speed and 
time, the minimum needed time to dissolve the components and the maximum time 
of mixing can affect the viscosity of the product (causing product failure) and it 
should be identified [22, 25, 26].
2.5 Critical material attributes (CMAs)
The quantitative and qualitative information of active pharmaceutical ingredi-
ents (API) is prime attributes as material attributes [11]. Although an API is mostly 
incorporated at low concentrations and occupies a negligible part in the final formu-
lation, the additives (inactive ingredients) usually elucidate the physical properties 
of a formulation [11, 27]. A number of researches have shown that additive(s) can 
influence the fate of an API in dosage form [28, 29]. Different grades of additives 
show a substantial effect on quality attributes of the final product as well as the API 
stability in the product [30]. Impurities in a raw material may show a detrimental 
impact on the stability of API/additives. Another prime challenge during the design 
and development of a novel dosage form is the compatibility of additives and API.
2.6 Design of experiments (DOEs)
The DOEs is not a replacement for experience, intelligence, or expertise; it is a 
precious element for choosing experiments systematically and efficiently to give 
dependable and coherent information [31]. DOEs are defined as “an organized, 
structured technique for deciding the relationship between attributes influencing 
a process and the output of the process” [32]. The DOEs can be applied for the 
screening of designs/experiments, comparative experiments, response surface 
methodology, and regression analysis [33].
2.6.1 Common experimental designs
In order to provide a logical relationship among the dependent variables and 
independent variables, experimental designs may be classified into four classes: a) 
screening designs, b) optimization designs [34–36] c) comparative experiments, 
and d) regression modelling.
2.6.1.1 Screening of designs/experiments
Screening of designs involves the selection of prime factors affecting a response. 
For the selection of experiments; fractionate factorial designs, the full factorial 
designs, and Placket-Burman designs are mostly used for screening because these 
designs have cost-effective advantages. These screening designs permit one to study 
various input factors with minimum numbers of experiments. However, these 
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designs also show some limitations that should be contemplated in order to impart 
a better interpretation of the effects of input elements on output responses [34–36]. 
Only the linear responses are supported by screening designs. Thus, if a nonlinear 
response is observed, or a more accurate phenomenon of the response surface is 
required or more complex design may be applied [37].
2.6.1.2 The factorial approach
The full factorial and fractional factorial designs are generally used by the most 
of the researchers as an alternative methodological technique to standard relative 
randomized controlled trials (RCTs) and module designs, which has supremacy 
over both for determining the active elements of formulations. The factorial designs 
are employed to explore the prime impacts of critical factors and interactions 
among factors [38–42].
The common and simple full factorial design is the 22 factorial designs, where 22 is 
indicating two factors at two levels means the total run of experiments is four, which 
are located in 2-dimensional factor space at the rectangle’s corners. If there are 23 fac-
torial designs is applied then total eight experiments are mandatory which are located 
at the corners of an orthogonal hexahedron on a 3-dimensional space. If large num-
bers of factors are used at large numbers of levels then the number of runs needed to 
finish the task. To minimize the number of runs, the fractional factorial design should 
be used (i.e., ½ or ¼ of the real number of runs of full factorial design) [43–45].
Table 2 shows the three factors at two coded levels 0 and 1, where 0 represents a 
low level and 1 represents a high level. In Table 2, the last column shows the response 
values of random variables. The main effect of any factor (A, B, C) or interaction 
(AB, AC, BC, ABC) is the difference of two means, the means of the responses cor-
responding to high levels and the means of responses corresponding to low levels.
When we compare the suggestions of Table 2 with the suggestions of fractionate 
factorial design shown in Table 3. In Table 3, every-even numbered test experiment 
eliminated from Table 2. Again, factor effects are differences in mean responses. 
Even though, the prime effect for factor A is absolutely similar and opposite in sign 
from the interaction AB; i.e., A is aliased with -AB. Each result in Table 3 is aliased 
with another result, having the prime result for B which is aliased with the evalua-
tion of the overall average response. Therefore, every difference in means measures 
the difference of two results; e.g., A-AB. Had the half-fraction accompanied the 
odd-numbered test experiments been removed, every difference of means for a 
result would be evaluating the sum of two results; e.g., A + AB.
Experiment A B C AB AC BC ABC Response
1 0 0 0 1 1 1 0 R1
2 0 0 1 1 0 0 1 R2
3 0 1 0 0 1 0 1 R3
4 0 1 1 0 0 1 0 R4
5 1 0 0 0 0 1 1 R5
6 1 0 1 0 1 0 0 R6
7 1 1 0 1 0 0 0 R7
8 1 1 1 1 1 1 1 R8
Table 2. 
Full factorial design with three factors at two levels.
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Every fractional factorial design needs the aliasing of all or some of the factor 
effects. Many times the selection of fractional factorial designs is the unscientific 
that can lead to ambiguity, even wrong, conclusions about factor effects. Inversely, 
it is precisely the attentive selection of which fraction is applied that can increase 
the experimentation efficiently without the aliasing of main effects. Table 4 shows 
another half-fraction of the full factorial design.
2.6.1.3 Plackett-Burman designs or Hadamard designs
This design is special two-level full factorial design and generally employed for 
the screening of factors. Plackett-Burman designs are mainly applicable for screening 
a large number of factors if we want to test the effect of 7 factors then we have to put 
some dummy factors. The results of full factorial designs, Plackett-Burman design, 
and Taguchi design are interpreted by using a half-normal plot and Pareto chart. By 
using these designs we can detect all prime effects economically and all other interac-
tions assumed as negligible when compared with few prime effects [46–48].
2.6.1.4 Response surface methodology (RSM)
Response surface methodology is used after the identification of the critical 
variables affecting a response. Response surface methods such as central composite 
design, Box–Behnken design, and three-level factorial designs can recognize the 
optimum/suitable processing parameters or conditions [49, 50]. The primary 
advantages of response surface methodology are as hitting a target, minimizing 
or maximizing a response, minimizing variations, setting a robust process, and 
finding multiple objectives.
2.6.1.5 Central composite designs or Box-Wilson design
This is one of the most commonly employed optimization design because 
this is used for 5 levels of each loaded factor with a less number of runs required 
when compared with 3 levels full factorial designs. Central composite designs are 
Experiment A B C AB AC BC ABC Response
1 0 0 0 1 1 1 0 R1
3 0 1 0 0 1 0 1 R3
5 1 0 0 0 0 1 1 R5
7 1 1 0 1 0 0 0 R7
Table 3. 
Fractional factorial design of a full factorial design with three factors.
Experiment A B C AB AC BC ABC Response
2 0 0 1 1 0 0 1 R2
4 0 1 1 0 0 1 0 R4
6 1 0 0 0 0 1 1 R6
8 1 1 1 1 1 1 1 R8
Table 4. 
Fractional factorial design of a full factorial design, prime results can be estimated.
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generally used for nonlinear responses. In this model, a two-factor central com-
posite design is similar to a 32 factorial design by using the experimental domain 
at α = ±1. Dash RN et al. successfully developed a glipizide-loaded formulation by 
using central composite designs [51].
2.6.1.6 Box–Behnken design
This is a specially made design, which needs only three levels for each factor 
and it is widely employed in response surface methodology for fitting second-order 
models for all responses. In this method, 15 experiments are run three levels for each 
factor. Box–Behnken designs are a combination of incomplete block designs with 
two-level factorial designs and these are almost rotatable. This design has the ben-
efits that there are no runs where three levels for each factor and that there are no 
corner points run. Runs at the corner points may be expensive or inconvenient [52].
2.6.1.7 Three level factorial designs
This design is mainly used only for two-three factors because the large numbers 
of runs are needed. The required number of runs may be calculated as 3 K, where K 
is selected factor for study.
2.6.1.8 Comparative experiments
Comparative studies are performed for selecting a suitable one between two/
more alternatives. From a sample of data, the mean results are generated and com-
pared for suitable selection from each alternative. For example, the selection of a 
vendor for a medicament from two/more vendors can be a relative experiment. The 
narrow scoped comparative designs are good for an initial comparison and broad 
scope design is appropriate for a confirmatory comparison [53].
2.6.1.9 Regression modelling
Regression modelling is an essential statistical component for the analysis of 
the data. It is employed for the identification and depiction of relationships among 
various factors. It is also used for the identification of prognostically pertinent risk 
elements and the determination of risk results for each prognostication [54]. The 
most commonly used regression techniques are the following: Linear regression, 
Cox regression, and Logistics regression. Regression modelling is used for the statis-
tical evaluation of the data by enabling three things: (a) Description analysis shows 
the relationship among the independent variables and the dependent variables and 
it can be statistically defined. (b) Estimation of the data for the dependent variables 
can be estimated from defined data of the independent variables. (c) Prediction of 
risk elements that influence the results can be identified, and individual prediction 
can be determined [55].
3. Conclusion
The ever-rising cost of novel dosage form development projects have not pro-
vided assurance of increased efficiency for delivering new drugs. In recent times, 
quality by design has shown great attention and is being spotlighted more than pre-
viously among pharmaceutical producers. Although consideration about its nomen-
clature and concepts remains indistinct, that may result in a lack of confidence 
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in applying the smart dosage form development. Knowing the disadvantages of 
quality by design on the one hand and in the other hand, getting a comprehensive 
understanding of quality by design can enable pharmaceutical manufacturers for 
employing the concepts of quality by design in utilization.
Robust manufacturing of smart pharmaceutical dosage forms, with their numer-
ous complex formulations and the necessity for rigid similarity with the commercial 
formulations, essential for the understanding of CPPs and CMAs. The details 
collected from the development of novel dosage form overtime at laboratory scale 
provide the substructure for pivotal or pilot scale development. Statistical tools 
help not only in understanding and identifying CMAs and CPPs in dosage form 
development, but also in comprehension of the role and relationship between these 
in attaining a target quality. Although, the implementation of statistical approaches 
in the development of dosage form is strongly recommended. From a commercial 
point of view, at all stages of product development, the implementation of quality by 
design reduces the costs and accelerates the process of product commercialization.
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